medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2016, Número 2

<< Anterior Siguiente >>

Biotecnol Apl 2016; 33 (2)


Congreso Internacional del Hígado 2016, abril 13-17, 2016, Barcelona, España

Aguilar RJC

Idioma: Ingles.
Referencias bibliográficas: 19
Paginas: 2501-2505
Archivo PDF: 228.74 Kb.


RESUMEN

En este reporte se destacan los más recientes descubrimientos presentados en la Reunión Anual de la Asociación Europea para el Estudio del Hígado (EASL), llamada Congreso Internacional del Hígado (ILC), celebrado en Barcelona, España, del 13 al 17 de abril. Sus temas principales fueron: hepatitis viral; cirrosis; inmunología e inflamación; trasplante; tumores; hígado graso; enfermedad inducida por fármacos; diagnóstico; biología molecular y celular; enfermedad hepática pediátrica; ensayos clínicos; enfermedades autoinmunes; marcadores de fibrosis y salud pública. Se discuten los hallazgos más relevantes acerca de los nuevos productos para el tratamiento de la hepatitis B crónica, y los desarrollos mostrados sobre las hepatitis C y D.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wong GLH, Tse YK, Wong V, Yip T, Chan H. Incidences of all malignancies in patients with chronic hepatitis B receiving long-term oral nucleos(t)ide analogue treatment – a study of 45’299 subjects. Section: Viral Hepatitis; Sub-section: Hepatitis B & D -clinical (therapy, new compounds, resistance). Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract PS052.

  2. European Association for the Study of the Liver. Treatment for chronic hepatitis B linked to increased rates of colorectal and cervical cancer. ScienceDaily. 2016 Apr 15 [cited 2016 May 30]. Available from: www.sciencedaily.com/releases/2016/04/160415081420.htm

  3. Johnson K. Release raises false alarm over Hep B meds and cancer risk. Medscape. 2016 Apr 22 [cited 2016 May 30]. Available from: http://www.medscape.com/viewarticle/862371

  4. Jiang L, Wu X, He F, Liu Y, Hu X, Takeda S, et al. Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog. PLoS One. 2016;11(1):e0147440.

  5. Food and Drug Administration. Baraclude Product Insert NDA 21-797-S-001. 2007 [cited 2016 May 22]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021797s001,021798s001lbl.pdf

  6. Food and Drug Administration. Viread Product Insert. 2012 [cited 2016 May 22]. Available from: http://www.accessdata. fda.gov/drugsatfda_docs/label/2012/02 1356s042,022577s002lbl.pdf

  7. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, doubleblind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606-15.

  8. Buti M, Gane E, Seto WK, Chan HLY, Chuang WL, Stepanova T, et al. A phase III study of Tenofovir Alafenamide compared with Tenofovir Disoproxil Fumarate in patients with HBeAg-negative, chronic hepatitis B: Week 48 efficacy and safety results. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract GS06.

  9. Chan HLY, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. A phase III study of Tenofovir Alafenamide compared with Tenofovir Disoproxil Fumarate in patients with HBeAg-positive, chronic hepatitis B: Week 48 efficacy and safety results. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract GS12.

  10. Chang Y, Lee JH, Nam JY, Ahn H, Cho H, Cho Y, et al. Nucleos(t)ide analogue treatment for immune tolerant phase of Chronic Hepatitis B patients prolongs overall survival and reduces the risk of hepatocellular carcinoma and cirrhosis: a real-life study. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract PS049.

  11. Yuen MF, Kim DJ, Weilert F, Chan HLY, Lalezari JP, Hwang SG, et al. NVR 3-778, A first in class HBV core inhibitor, alone and in combination with Peg-Interferon (PegIFN), in treatment-naïve HBeAgpositive patients: Early reductions in HBV DNA and HBeAg. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract, Late Breaker.

  12. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87.

  13. Kwo PY, Wyles DL, Wang S, Poordad F, Gane E, Maliakkal B, et al. SURVEYOR-II: 100% SVR12 with ABT-493 and ABT-530 with or without ribavirin in treatment-naive HCV genotype 3-infected patients with cirrhosis. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract LBO1.

  14. Wang GP, Reeves JD, Terrault N, Lim JK, Morelli G, Kuo A, et al. Prevalence and impact of baseline resistance-associated variants on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection: HCV-TARGET interim analysis. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract PS102.

  15. Deterding K, Spinner C, Schott E, Welzel T, Gerken G, Klinker H, e. Six weeks of sofosbuvir/ledipasvir (SOF/ LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET Acute HCV IV Study. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract LBO8.

  16. Fernández-Carrillo C, Lens S, Llop E, Pascasio JM, Fernandez I, Baliellas C, et al. Treatment of hepatitis C virus in patients with advanced cirrhosis: always justified? Analysis of the HEPA-C registry. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract GS01.

  17. Kattakushy S, Gross C, Teferi G, Jenkins V, Silk R, Akoth E, et al. A novel task shifting model to expand the HCV care continuum: the ascend investigation. Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract LBP524.

  18. Wrankle A, Serrano BC, Heidrich B, Kirschner J, Bremer B, Hardtke S, et al. Does antiviral treatment affect the clinical long-term outcome of Hepatitis Delta? Section: Viral Hepatitis; Sub-section: Hepatitis B & D –clinical (therapy, new compounds, resistance). Program and abstracts of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract GS053.

  19. European Association for the Study of the Liver. Study demonstrates benefits of existing treatment for hepatitis D patients. ScienceDaily. 2016 Apr 15 [cited 2016 May 30]. Available from: https://www.sciencedaily.com/releases/ 2016/04/160415081411.htm




2020     |     www.medigraphic.com